Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Bank of New York Mellon Corp Has $1.30 Billion Holdings in Stryker ...

📉 Bank of New York Mellon Corp reduced its Stryker stake by 8.3% in Q1, selling 359,418 shares while retaining a $1.3 billion position.

📈 Multiple hedge funds and institutional investors initiated new positions in SYK during the third and fourth quarters.

💰 Institutional ownership of Stryker Corporation stands at 77.09% as of the latest SEC filings.

🎯 BTIG Research set a $371 target price, while Canaccord Genuity lowered its target to $400 but maintained a 'buy' rating.

📊 Goldman Sachs restated a neutral rating with a $361 target, and BMO Capital Markets initiated coverage with an 'outperform' rating.

📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.

💵 Revenue for the quarter reached $6.02 billion, representing a 2.6% increase compared to the same period last year.

📉 The company missed revenue estimates of $6.34 billion and reported a net margin of 13.20%.

🔮 Stryker provided FY 2026 guidance for EPS between $14.90 and $15.10, slightly below analyst predictions of $14.98.

💸 The company declared a quarterly dividend of $0.88 per share with an ex-dividend date of June 30th.

📉 Director Ronda E. Stryker sold 310,000 shares worth approximately $96.8 million in a recent transaction.

📉 VP Robert S. Fletcher sold 4,544 shares worth approximately $1.4 million under a pre-arranged trading plan.

📉 Insiders have collectively sold 323,264 shares worth over $100.6 million over the last 90 days.

📈 The stock trades at a market cap of $121.32 billion with a PEG ratio of 1.99 and a beta of 0.77.

📉 Shares opened at $316.46, trading above the 50-day moving average but below the 200-day moving average.

Bullish Signals
  • Multiple institutional investors and hedge funds initiated new positions in Stryker during Q3 and Q4, indicating continued interest from capital markets.
  • Stryker achieved a 2.6% year-over-year revenue increase to $6.02 billion despite missing analyst expectations.
  • The company maintains a healthy net margin of 13.20% and a return on equity of 23.42%.
  • Analyst consensus remains 'Moderate Buy' with an average target price of $392.52, which is above the current trading price.
  • BMO Capital Markets initiated coverage with an 'outperform' rating and a $369 target price.
  • Stryker has a strong balance sheet with a current ratio of 2.11 and a debt-to-equity ratio of 0.62.
Risk Factors
  • Stryker missed Q1 earnings estimates by $0.38 per share, reporting $2.60 EPS against a consensus of $2.98.
  • Revenue of $6.02 billion fell short of the $6.34 billion analyst estimate for the quarter.
  • Canaccord Genuity reduced its price target from $435 to $400, reflecting some near-term concerns.
  • Goldman Sachs restated its rating to 'neutral' with a lower $361 price target.
  • Significant insider selling occurred recently, with Director Ronda E. Stryker and VP Robert S. Fletcher reducing their holdings by 13.87% and 30.04% respectively.
  • Insiders have sold over $100 million worth of stock in the last 90 days, totaling 4.60% of outstanding shares.
Full Analysis
Bank of New York Mellon Corp reduced its stake in Stryker Corporation (NYSE:SYK) by 8.3% in the first quarter, selling 359,418 shares to hold a remaining position of 3,952,401 shares valued at approximately $1.3 billion. While BNY Mellon decreased its holding, several other institutional investors and hedge funds initiated new positions in the fourth or third quarters, with stakes ranging from roughly $26,000 to $28,000 each, contributing to a total institutional ownership of 77.09%. Analyst sentiment remains mixed but generally positive regarding Stryker's long-term prospects. BTIG Research set a $371 target price, while Canaccord Genuity lowered its target from $435 to $400 but maintained a 'buy' rating. Goldman Sachs restated a neutral rating with a $361 target, and BMO Capital Markets initiated coverage with an 'outperform' rating and $369 target. The consensus average target price stands at $392.52 based on data from MarketBeat.com. Financially, Stryker reported Q1 earnings of $2.60 per share, missing the consensus estimate of $2.98 by $0.38, with revenue of $6.02 billion falling short of the $6.34 billion expected. Despite the miss, revenue grew 2.6% year-over-year to a net margin of 13.20%. The company has provided FY 2026 guidance for EPS between $14.90 and $15.10, while insiders have sold significant shares recently, including Director Ronda E. Stryker selling over $96 million worth of stock. The stock currently trades at a market cap of $121.32 billion with a price-to-earnings ratio of 36.63 and a beta of 0.77. Shares opened at $316.46, trading above its 50-day moving average but below its 200-day average. Stryker also declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record on June 30th, representing an annualized yield of 1.1% and a payout ratio of 40.74%.